AVIDICURE
DEAD

Serial Number

79393448

Owner

Avidicure B.V.

Attorney

Roberto Ledesma

Filing Date

Jan 26, 2024

Add to watchlist:

No watchlists yet
View on USPTO

AVIDICURE Trademark

Serial Number: 79393448

AVIDICURE is a trademark filed by Avidicure B.V. on January 26, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently no longer active.

Owner Contact Info

Avidicure B.V.

Gooimeer 2 35

Entity Type: 99

Trademark Details

Filing Date

January 26, 2024

Registration Date

Not Registered

Goods & Services

Chemical products for use in industry, science, and photography, namely, monoclonal antibodies and recombinant proteins used in scientific in-silico, in-vitro, in-vivo, and clinical research and development relating to immuno-oncology.

Legal services relating to the exploitation of patents; management and licensing of patents; licensing of intellectual property

Medical services; medical and pharmaceutical advisory and consultancy services; medical care services

Pharmaceutical substances and preparations for human use, namely for treatment for cancer, inflammatory diseases, auto immune diseases, and infectious diseases; biopharmaceutical substances and preparations for human use, namely for treatment for cancer, inflammatory diseases, auto immune diseases, and infectious diseases.

Medical and scientific research services; industrial research services in the field of treatment for cancer, inflammatory diseases, auto immune diseases and infectious diseases; pharmaceutical and biopharmaceutical research and development services; development, research, laboratory analysis and testing of pharmaceutical and biopharmaceutical drugs and semi-finished chemicals and chemical products for use in pharmaceuticals; development of test systems in the nature of cell culture models, animal models and companion diagnostics for pharmaceutical and biopharmaceutical products; chemical analysis; computer system analysis and programming, namely, the development of prototypes and collection and processing of medical data for scientific research, development of databases in the medical, pharmaceutical and biopharmaceutical fields.

Educational services, namely, arranging and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug research, or drug and pharmaceutical development; training services, namely, providing training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug research, or drug and pharmaceutical development.

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Sep 27, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 10, 2025 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Sep 10, 2025 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
Sep 5, 2025 NREP
ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT
Aug 2, 2025 MAB1
ABANDONMENT - EXPRESS MAILED
Aug 2, 2025 ABN1
TEAS EXPRESS ABANDONMENT RECEIVED
Aug 1, 2025 EXAR
REFUSAL PROCESSED BY IB
Mar 22, 2025 RFNT
NON-FINAL ACTION WRITTEN
Feb 18, 2025 CNRT
EXAMINER'S AMENDMENT ENTERED
Jan 21, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 21, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 21, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 21, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 19, 2024 TROA
REFUSAL PROCESSED BY IB
Sep 14, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Aug 28, 2024 RFCS
REFUSAL PROCESSED BY MPU
Aug 27, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 23, 2024 RFCR
NON-FINAL ACTION WRITTEN
Aug 22, 2024 CNRT
ASSIGNED TO EXAMINER
Aug 21, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 18, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 12, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 11, 2024 REPR